Trials / Recruiting
RecruitingNCT06765668
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Impax Laboratories, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CREXONT ER | CREXONT ER capsule. |
Timeline
- Start date
- 2025-02-12
- Primary completion
- 2025-11-01
- Completion
- 2026-08-06
- First posted
- 2025-01-09
- Last updated
- 2025-08-24
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06765668. Inclusion in this directory is not an endorsement.